BRCA1

(redirected from BRCAI)
Also found in: Dictionary.

BRCA1

symbol for a breast cancer gene. BRCA1 is a tumor suppressor gene. A healthy BRCA1 gene produces a protein that protects against unwanted cell growth. The protein is packaged by the cell's Golgi apparatus into secretory vesicles, which release their contents on the cell's surface. The protein circulates in the intracellular space, attaching itself to neighboring cell receptors. The receptors signal the cell nuclei to stop growing. When the gene is defective, it produces a faulty protein that is unable to prevent proliferation of abnormal cells as they evolve into potentially deadly breast cancer. BRCA1 may also normally inhibit ovarian cancer.

BRCA1

A gene on chromosome 17q21, which encodes a protein that plays a role in maintaining genomic stability and acts as a tumour suppressor. It combines with other tumour suppressors, DNA damage sensors and signal transducers to form a large multi-subunit-protein complex known as the BRCA1-associated genome surveillance complex (BASC), which associates with RNA polymerase II and histone deacetylase complexes, thus playing a role in transcription, DNA repair of double-stranded breaks and recombination. BRCA1 mutations cause 40% of inherited breast cancers and over 80% of inherited breast and ovarian cancers.

BRCA1

Molecular oncology A large tumor suppressor gene on chromosome 17 which is linked to breast, ovarian, prostate and other CAs; Pts with BRCA1 represent 5% of all breast CAs; ♀ with BRCA1 have an 85% chance of developing breast CA before age 65; mutations of BRCA1 are common in Ashkenazi Jews Lab BRCA1 and BRCA2 are part of some commercial diagnostic labs' genetic services. See Tumor suppressor gene.
References in periodicals archive ?
A little scientific summary of the technology in discussion: The test Jolie received works by screening for mutations in an individual's BRCAI and BRCA2 genes.
1994 The complete sequence of BRCAI gene is identified, including specific mutations related to hereditary breast and ovarian cancer, by a collaborative effort led by Mark Skolnick at the University of Utah Medical Center.
The District Court of the Southern District of New York issued a recent opinion overturning patents on the isolated BRCAI and BRCA2 genes.
This paper reports on women with proven inherited disease-predisposing BRCAI and BRCA2 mutations participating in the Prevention and Observation of Surgical Endpoints (PROSE) consortium multicentre study, who were ascertained to carry the high-risk predisposition gene between 1974 and 2008 [1].
A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI.
Genetic Testing and Adverse Selection in the Market for Life Insurance: Preliminary Findings for The BRCAI Gene Mutation, in GENETIC INFORMATION: ACQUISITION, ACCESS, AND CONTROL 57, 57 (Alison K.
In the women who underwent oophorectomy, the team first looked at the entire group, BRCAI and BRCA2 together.
Cost of Genetic counseling for BRCAI and BRCA2 Breast cancer susceptibility Mutations.
In the case of "defective" mutations of the BRCAI or BRCA2 gene associated with breast or ovarian cancer, approximately 50% to 60% of women who inherit those genes will actually develop cancer during their lifetimes.
SAN ANTONIO -- Women with bilateral invasive breast cancer have a high prevalence of BRCAI and BRCA2 mutations regardless of whether they possess a strong family history of breast or ovarian cancer, Alicia A.